Kinnate Biopharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.85
- Today's High:
- $1.98
- Open Price:
- $1.92
- 52W Low:
- $1.84
- 52W High:
- $12.965
- Prev. Close:
- $1.92
- Volume:
- 158354
Company Statistics
- Market Cap.:
- $111.61 million
- Book Value:
- 4.2
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -30.75%
- Return on Equity TTM:
- -50.22%
Company Profile
Kinnate Biopharma Inc had its IPO on 2020-12-03 under the ticker symbol KNTE.
The company operates in the Healthcare sector and Biotechnology industry. Kinnate Biopharma Inc has a staff strength of 84 employees.
Stock update
Shares of Kinnate Biopharma Inc opened at $1.92 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.85 - $1.98, and closed at $1.89.
This is a -1.56% slip from the previous day's closing price.
A total volume of 158,354 shares were traded at the close of the day’s session.
In the last one week, shares of Kinnate Biopharma Inc have slipped by -19.57%.
Kinnate Biopharma Inc's Key Ratios
Kinnate Biopharma Inc has a market cap of $111.61 million, indicating a price to book ratio of 1.0635 and a price to sales ratio of 0.
In the last 12-months Kinnate Biopharma Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-132066000. The EBITDA ratio measures Kinnate Biopharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Kinnate Biopharma Inc’s operating margin was 0% while its return on assets stood at -30.75% with a return of equity of -50.22%.
In Q2, Kinnate Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Kinnate Biopharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.88 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kinnate Biopharma Inc’s profitability.
Kinnate Biopharma Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.3362. Its price to sales ratio in the trailing 12-months stood at 0.
Kinnate Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $216.14 million
- Total Liabilities
- $15.77 million
- Operating Cash Flow
- $-10884000.00
- Capital Expenditure
- $9000
- Dividend Payout Ratio
- 0%
Kinnate Biopharma Inc ended 2024 with $216.14 million in total assets and $0 in total liabilities. Its intangible assets were valued at $216.14 million while shareholder equity stood at $197.62 million.
Kinnate Biopharma Inc ended 2024 with $0 in deferred long-term liabilities, $15.77 million in other current liabilities, 5000.00 in common stock, $-324221000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $34.51 million and cash and short-term investments were $184.70 million. The company’s total short-term debt was $959,000 while long-term debt stood at $0.
Kinnate Biopharma Inc’s total current assets stands at $188.60 million while long-term investments were $19.58 million and short-term investments were $150.20 million. Its net receivables were $0 compared to accounts payable of $2.70 million and inventory worth $0.
In 2024, Kinnate Biopharma Inc's operating cash flow was $-10884000.00 while its capital expenditure stood at $9000.
Comparatively, Kinnate Biopharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.89
- 52-Week High
- $12.965
- 52-Week Low
- $1.84
- Analyst Target Price
- $20.34
Kinnate Biopharma Inc stock is currently trading at $1.89 per share. It touched a 52-week high of $12.965 and a 52-week low of $12.965. Analysts tracking the stock have a 12-month average target price of $20.34.
Its 50-day moving average was $2.63 and 200-day moving average was $4.6 The short ratio stood at 8.31 indicating a short percent outstanding of 0%.
Around 20.6% of the company’s stock are held by insiders while 10383.3% are held by institutions.
Frequently Asked Questions About Kinnate Biopharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.